COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Conditions: Advanced Cancer; Ovarian Cancer; Breast Cancer; Lung Cancer; Endometrial Cancer; Ovarian Neoplasm; Triple Negative Breast Cancer; Lung Neoplasm; Neoplasm Malignant; Colo-rectal Cancer
Interventions: Drug: COM701; Drug: COM701 with Opdivo (Nivolumab).
Sponsors: Compugen Ltd; Bristol-Myers Squibb
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 14, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments